Free Trial
→ A grave, grave error. (From Porter & Company) (Ad)
NASDAQ:GLMD

Galmed Pharmaceuticals 11/22/2023 Earnings Report

Galmed Pharmaceuticals logo
$1.36 -0.12 (-8.11%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 +0.02 (+1.40%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Galmed Pharmaceuticals EPS Results

Actual EPS
-$2.88
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Galmed Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galmed Pharmaceuticals Announcement Details

Quarter
Date
11/22/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Galmed Pharmaceuticals' next earnings date is estimated for Wednesday, May 28, 2025, based on past reporting schedules.

Conference Call Resources

Galmed Pharmaceuticals Earnings Headlines

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
May 27 at 8:00 AM | prnewswire.com
GALMED PHARMACEUTICALS Earnings Results: $GLMD Reports Quarterly Earnings
May 24, 2025 | nasdaq.com
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
May 28, 2025 | Brownstone Research (Ad)
Galmed Pharmaceuticals (NASDAQ:GLMD) Rating Increased to Sell at Wall Street Zen
May 24, 2025 | americanbankingnews.com
Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 22, 2025 | finanznachrichten.de
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 22, 2025 | prnewswire.com
See More Galmed Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galmed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galmed Pharmaceuticals and other key companies, straight to your email.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals (NASDAQ:GLMD), a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

View Galmed Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles